Vanadis NIPT System

Easy. Precise. Cost-effective.

Vanadis® NIPT system is an automated cell-free DNA testing platform designed to make noninvasive prenatal testing accessible to more women – and more cost-effective for your laboratory.

For in vitro diagnostic use. This product is only available where licensed in accordance with law. Please contact your local representative for availability.

Request more information Sign up for newsletter

Walkaway automation for greater efficiency

With Vanadis technology, all the critical steps are automated, starting with pipetting steps to reduce manual errors. Plasma volumes are monitored by camera to avoid contamination by the buffy coat, and samples and reagents are barcoded for complete tracking throughout the workflow. Our software guides you through the process, with user-friendly touchscreens, enabling remote workflow management for ease of use. Easy to integrate, our software is designed for LIMS connectivity, reducing manual errors while simplifying data management.

Groundbreaking cfDNA technology: No PCR, no sequencing

Vanadis is the only NIPT screening platform to enable targeted cfDNA analysis without PCR, instead directly capturing target fragments and labeling them for counting. A proprietary nanofilter plate then captures labeled molecules for imaging, eliminating the need for data-intensive steps such as DNA sequencing, microarrays, and microfluidics.

Workflow: Streamlined workflow from primary tube to final result

Screen for the risk of trisomies 21, 18, 13, as well as fetal sex determination with Vanadis NIPT. By targeting thousands of chromosomal sequences, the Vanadis system can bring high precision non-invasive prenatal testing to your lab, counting an average of 650,000 molecules per chromosome.

Benefits for your laboratory

Kits: Proven clinical performance

Clinical studies have demonstrated that the Vanadis NIPT system could improve detection and false positive rates, while minimizing the number of no-calls.

Products comprising the Vanadis NIPT system are CE-marked in vitro diagnostic products in accordance with European directive 98/79/EC.

	Trisomy 21	Trisomy 18	Trisomy 13
Detection Rate (95% CI)	100% (80/80) (95.5%-100%)	91.4% (32/35) (76.9%-98.2%)	100% (10/10) (69.2%-100%)
False Positive Rate (95% CI)	0.0% (0/666) (0.0%-0.6%)	0.2% (2/1033) (0.0%-0.7%)	0.1% (1/1033) (0.0%-0.5%)
The observed no-call rate: 0.94% (after first pass)

Trisomy 21

Trisomy 18

Trisomy 13

Detection Rate (95% CI)

100%

(80/80)

(95.5%-100%)

91.4%

(32/35)

(76.9%-98.2%)

100%

(10/10)